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Abstract: Ischemic heart conditions are among the main causes of sudden 
cardiac death worldwide. One of the strategies for avoiding myocardial 
infarction is the low-dose, prophylactic use of acetylsalicylic acid 
(ASA), an inhibitor of platelet aggregation. To avoid the 
gastrointestinal damage, ASA prodrugs bearing nitric oxide (NO)-donating 
moiety covalently conjugated to ASA have been synthesized and evaluated 
extensively worldwide. Herein the synthesis of a new hybrid ASA ester 
covalently attached to the NO donor linsidomine, an active metabolite of 
molsidomine (MOL) is reported. Cell viability assay and hemolysis tests 
were performed in H9c2 cells and rat erythrocytes, respectively. Our new 
compound, the ERJ-500 not affected negatively the viability of living 
cells in the concentration range of 100 nM to 100 µM. Using the ex vivo 
Langendorff method on hearts originated from female rats, compound ERJ-
500 displayed a dose-dependent, outwashable vasodilative effect in 
coronary arteries. Vasodilation was observed on isolated working heart 
model as well, with elevated stroke volume in hearts treated with ERJ-
500. Furthermore, a decreased infarct size was also noticed in ERJ-500 
treated hearts after ischemia/reperfusion. Based on these observations it 
can be expected that our new hybrid ASA may contribute to new 
pharmacological tool in the therapy of ischemic heart conditions and 
associated syndromes. 
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ABSTRACT 30 
Ischemic heart conditions are among the main causes of sudden cardiac death worldwide. One 31 
of the strategies for avoiding myocardial infarction is the low-dose, prophylactic use of 32 
acetylsalicylic acid (ASA), an inhibitor of platelet aggregation. To avoid the gastrointestinal 33 
damage, ASA prodrugs bearing nitric oxide (NO)-donating moiety covalently conjugated to 34 
ASA have been synthesized and evaluated extensively worldwide. Herein the synthesis of a 35 
new hybrid ASA ester covalently attached to the NO donor linsidomine, an active metabolite 36 
of molsidomine (MOL) is reported. Cell viability assay and hemolysis tests were performed in 37 
H9c2 cells and rat erythrocytes, respectively. Our new compound, the ERJ-500 not affected 38 
negatively the viability of living cells in the concentration range of 100 nM to 100 µM. Using 39 
the ex vivo Langendorff method on hearts originated from female rats, compound ERJ-500 40 
displayed a dose-dependent, outwashable vasodilative effect in coronary arteries. Vasodilation 41 
was observed on isolated working heart model as well, with elevated stroke volume in hearts 42 
treated with ERJ-500. Furthermore, a decreased infarct size was also noticed in ERJ-500 43 
treated hearts after ischemia/reperfusion. Based on these observations it can be expected that 44 
our new hybrid ASA may contribute to new pharmacological tool in the therapy of ischemic 45 
heart conditions and associated syndromes. 46 
 47 
 48 
 49 
 50 
 51 
 52 
Keywords 53 
Acetylsalicylic acid, molsidomine, synthesis, nitrogen oxide liberation, isolated heart, 54 
vasoactivity, coronary flow. 55 
 56 
 57 
 58 
 59 
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1. INTRODUCTION 60 
 61 
Acetylsalicylic acid (ASA), also known as aspirin - the oldest non-steroidal anti-inflammatory 62 
drug (NSAID) - is extensively used for the treatment of pain and inflammation and because of 63 
its antithrombotic properties, it is also commonly used for the prophylaxis against myocardial 64 
infarction and stroke. The anti-inflammatory action of ASA is based on the inhibition of 65 
cyclooxygenase (COX1 and COX2) enzymes involved in prostaglandin (PG) biosynthesis [1]. 66 
However, ASA is a much more potent inhibitor of COX1 isoenzyme than that of COX2 [2]. 67 
Moreover, ASA irreversibly inhibits COX1 in platelets, consequently resulting in the 68 
inhibition of thromboxane A2 biosynthesis [3]. Since thromboxane A2 is a potent platelet 69 
aggregator and causes vasoconstriction, this inhibitory process affects the antiplatelet-70 
aggregation property of ASA. Low-dose, long-term prophylactic use of ASA is limited by its 71 
strong local irritant effects and gastrotoxicity [4, 5] and ulcerative ability. 72 
There is an increasing number of experimental data supporting basic physiological and 73 
protective roles of nitrogen monoxide, also called nitric oxide (NO), and nitrogen monoxide-74 
releasing molecules (NMRMs) in injured tissues [6-9]. The main source of endogenous NO is 75 
nitrogen monoxide synthase (NOS). NOS/NO system was proved to play an important role in 76 
signaling mechanisms and several physiological processes, including the maintenance of 77 
neuronal [10], immune [11], and cardiovascular functions [12]. Moreover, NO acts as a 78 
crucial signaling molecule and an effector mediator to regulate the coronary artery function in 79 
the myocardium [13]. However, overexpression of inducible NOS and its consequence, an 80 
extensive increase in endogenous NO production may not be beneficial for the myocardium 81 
[14, 15]. On the other hand, molecules releasing NO including molsidomine (MOL) are used 82 
as antihypertensive and antianginal drugs.   83 
The strategy for avoiding the systemic gastrointestinal damage, ASA prodrugs bearing 84 
nitrogen monoxide (NO)–donating moiety covalently attached to the carboxylic function of 85 
ASA were designed since locally released NO is able to trigger anti-inflammatory effects [16, 86 
17]. Nitrate ester [18-20], furoxan [21], or diazenium-diolate derivatives [22-24] have been 87 
attached covalently to ASA to form ester-type prodrugs. The biological activity of these 88 
hybrid aspirins has been evaluated extensively. Thus, nitrate ester derivative NCX4016 89 
prevented thromboembolism and restenosis and protected the heart from ischemia/reperfusion 90 
injury in animal models [25] displaying no gastrotoxicity in the stomach. Further beneficial 91 
effects include the inhibition of platelet COX1 activation and favorable influence on platelet-92 
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activation function in healthy volunteers [25]. Additional advantageous properties of ASA 93 
and NMRMs include anti-inflammatory and gastrosparing activities [19-24]. Furthermore, 94 
various NO donors have been developed as pharmacological tools to induce the protective 95 
effect of the ischemic myocardium [26]. The NMRMs release NO into biological systems for 96 
therapeutic purposes in a controlled and safe manner [27]. The cardiovascular effects of 97 
NMRMs are currently under intensive investigation and various classes of compounds are 98 
being developed with the goal of exploiting therapeutic potentials in the treatment of 99 
inflammatory and cardiovascular diseases [28, 29]. Thus, it is quite rational to hypothesize 100 
that an NMRM bearing ASA and molsidomine may have vasoactive, and COX inhibitor 101 
activity. 102 
2. RESULTS AND DISCUSSION 103 
 104 
2.1 Chemistry 105 
Design and synthesis of ERJ-500 106 
Starting with a research program for the synthesis of new hybrid ASA derivatives we turned 107 
our attention to molsidomine (1) (3-morpholino-N-ethoxycarbonyl sydnonimine), which is a 108 
NO donor and used as a coronary vasodilator [30]
 
in patients suffering from coronary artery 109 
diseases. Compound 1 displayed protective effect on indomethacin and ASA-induced gastric 110 
injury in rats [31]. Moreover, molsidomine (MOL) has a significant platelet antiaggregatory 111 
activity in vitro [32]. We postulated that a hybrid derivative of ASA and MOL would exhibit 112 
advantageous and synergistic effects of the two drugs, i. e. diminished side effects of ASA 113 
and improved inhibition of platelet aggregation. The mesoionic MOL is metabolized in the 114 
following way (Scheme 1) [33]. 115 
 116 
Scheme 1. Metabolism of molsidomine (The carbamate moiety is highlighted in green) 117 
  118 
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The active metabolite is 2 (linsidomine, SIN-1), therefore, we hypothesized that its covalent 119 
conjugation to acetylsalicylic acid would result in a NO donor hybrid ASA. For the linkage 120 
between ASA and compound 2, we designed a tetraethyleneglycol chain to improve the water 121 
solubility of the product and a carbamate group, similar to that in compound 1. It is assumed 122 
that the planned ASA-MOL conjugate could serve as a NO donor with a similar mechanism to 123 
MOL, a drug already used for pharmacotherapy. Our goals practically in the present study 124 
were (i) to produce a new NO donor hybrid aspirin and (ii) to study its toxic and vasodilator 125 
effects, in the highlight of coronary artery dilation in the myocardium. 126 
For the synthesis of ERJ-500, acetylsalicylic acid chloride 3 [34] was reacted with mono-127 
triphenylmethyl tetraethyleneglycol 4 [35], obtaining the 5 ester. The trityl group was 128 
removed using a reagent cocktail [36] resulting in compound 6, which was allowed to react 129 
with linsidomine active carbamate ester 7 [37] to give ERJ-500, the desired hybrid ASA 130 
derivative (Scheme 2).  131 
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 132 
Scheme 2. Synthesis of ASA-molsidomine hybrid with a hydrolysable ester linkage (highlighted in yellow) and 133 
the metabolically labile carbamate moiety (highlighted in green) 134 
 135 
It is important to note that ERJ-500 proved to be stable after one-year long storage at room 136 
temperature (NMR analysis showed no degradation). 137 
Oxidative stability assays 138 
The oxidative stability of the ERJ-500 compound was assessed utilizing two novel 139 
biomimetic model systems. In the first set of experiments a synthetic porphyrin, Fe(III) meso-140 
tetra(4-sulfonatophenyl)porphine chloride was applied. The total ion chromatograms of the 141 
control and ERJ-500 after oxidation by synthetic porphyrin were almost identical, therefore 142 
the ERJ-500 molecule was resistant against simple oxidative conditions, which could 143 
possibly change the structure of the molecule in another case.  144 
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The oxidation of the ERJ-500 was done by the classical Fenton reaction as well. The reaction 145 
mixtures were analyzed by HPLC-MS/MS. Based on the recorded spectra of the control and 146 
test samples it can be concluded that the compound was stable under the applied conditions, 147 
as the peaks on the chromatogram were not changed notably after 1 hour of oxidation 148 
compared to the control chromatogram. The obtained results were identical to the ones 149 
achieved by the synthetic porphyrin oxidation, further confirming the stability of the new 150 
molecule under simple oxidative conditions. 151 
A sample chromatogram of each oxidative stability models mentioned above can be found in 152 
the supplementary material (Fig. S1 and S2).  153 
 154 
2.2 Biological studies 155 
 156 
Safety evaluation of ERJ-500 157 
To assess the direct cytotoxic effects of ERJ-500, we carried out MTT assays at different 158 
concentrations of the studied molecule, and its two constituents, ASA and MOL in H9c2 cells. 159 
A slight decrement can be seen in all treated groups compared to the control, but all treated 160 
groups resulted in a significantly higher cell viability compared to the positive control group, 161 
which was treated with 1% H2O2. No significant differences can be observed between the 162 
groups treated by ERJ-500 or other molecules studied (Figure 1.A.), therefore, we may 163 
conclude that ERJ-500 is an equally safe compound as the MOL or ASA.  164 
To confirm our previously demonstrated cytotoxicity results, we performed hemolytic activity 165 
studies in blood cells isolated from Sprague Dawley rats. The hemolytic activity in rat 166 
erythrocytes at different concentrations of ERJ-500, ASA and MOL were significantly lower 167 
compared to the positive control group (Figure 1.B.). Samples of the latter group received 168 
sterile water, which induced 100% hemolysis. No significant differences can be observed 169 
among the groups treated by ERJ-500, ASA, and MOL, respectively in hemolytic activities, 170 
which further confirm that our aspirin derivative  seems to be a safe compound. 171 
 172 
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Figure 1. Safety evaluation of ERJ-500 A. Cytotoxicity test. The bar chart represents cell survival rates in 175 
percentage compared to the control group, which served by the solvent only (phosphate buffered saline-PBS). 176 
ERJ-500 100 nM - 100 µM; ASA 100 µM; MOL 100 µM; and 1% H2O2. Results are expressed as mean ± SEM. 177 
n=20-67 cells in each group. *p <0.05 in comparison with the positive control group (Pos. control). 178 
B. Hemolysis test. The bars represent hemolytic activity in percentage referring to the control group, which 179 
contained the solvent (PBS) only. ERJ-500 100 nM – 100 µM, ASA 100 µM, MOL 100 µM. Results are 180 
expressed as mean ± SEM. n=8-11 in each group. *p < 0.05 in comparison with the positive control (H2O) group 181 
(Pos. control). 182 
 183 
Vasoactive effects of ERJ-500 184 
To study the vasoactive effects of the ERJ-500 in the myocardium, the drug was dissolved in 185 
the perfusion buffer at a concentration rate of 1 µM to 100 µM, and isolated hearts were 186 
perfused. During Langendorff perfusion, the ERJ-500 did not produce any incidence of 187 
ventricular tachycardia or ventricular fibrillation. In addition, heart rate was not significantly 188 
changed in comparison with the drug-free control group (Figure 2.A.). Coronary flow was 189 
significantly increased by about 50% in the group treated with 100 µM ERJ-500 (Figure 190 
2.B.). During Langendorff perfusion, the coronary flow is influenced by the heart rate, the 191 
perfusion pressure, and the coronary dimension. Since the perfusion pressure used in the 192 
present study is constant and the heart rate is not significantly altered, the increased coronary 193 
flow could be a result of the coronary relaxation.  Although in the present study, the 194 
concentration of NO was not directly measured, and it would be the subject of another study, 195 
our results support the hypothesis that NO may originate from the ASA-MOL compound 196 
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(ERJ-500), since salicylic acid shows no vasodilator activity in the myocardium [38, 39]. 197 
Cardioprotective effects of ASA and salicylic acid related derivatives can be attributed to 198 
affect the platelet activation related to cyclooxygenase enzyme activities (COX1 and COX2) 199 
and heat stress protein expression in the diseased myocardium [40, 41].  200 
To further confirm vasoactive effects of ERJ-500 and to study any possible beneficial effects 201 
of the compound on the mechanical activity of the hearts, we tested the molecule on the 202 
isolated working heart perfusion system as well, at a concentration, which seemed the most 203 
advantageous previously. In the working heart perfusion, when other mechanisms also 204 
involved to compensate measurable vasoactive effects, coronary flow was still significantly 205 
elevated in treated hearts with 100 µM ERJ-500 (Figure 2.D.). Stroke volume was also 206 
significantly increased, thus, ERJ-500 can be an additive effect to improve myocardial 207 
contraction force (Figure 2.E.). As previously measured in Langendorff heart preparation, 208 
heart rate did not change notably in working heart preparation also (Figure 2.C.). Rest of the 209 
measured, non-significant myocardial parameters can be found in the supplementary material. 210 
 211 
 212 
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 214 
Figure 2. Effects of ERJ-500 on cardiac functions of isolated Langendorff and working heart.  215 
A., Alteration of heart rate and B., coronary flow in the presence of the ERJ-500 at different concentrations (1-216 
100 µM) when the heart is mounted on the “Langendorff” apparatus. *p < 0.05 in comparison with the control 217 
values at the same time points. n=5 in each group. 218 
C., Alteration of heart rate, D., coronary flow, and E., stroke volume in the presence (ERJ-500) or the absence 219 
(Control) of 100 µM ERJ-500, when the heart is mounted on the isolated working heart apparatus. No significant 220 
differences were observed among groups. *p < 0.05 in comparison with the control values.  n=11 in the control 221 
group, n=6 in the treated group. 222 
 223 
Anti-ischemic effect of ERJ-500  224 
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To further analyze the effect of ERJ-500 on the rat myocardium, infarct size was evaluated 225 
using the triphenyl-tetrazolium-chloride-staining method (TTC). Following 30 min of 226 
ischemia and 90 min reperfusion, infarct zones of TTC-stained hearts were expressed in a 227 
percentage of the whole myocardium.  Figure 3. shows that hearts perfused with ERJ-500 228 
containing buffer resulted in a significantly decreased infarct size. 229 
This result indicates that ERJ-500 has a cardioprotective effect, which could be a consequence 230 
of the vasorelaxant property, however, other mechanisms may also contribute to this effect.   231 
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Figure 3. Effects of ERJ-500 on infarct site. Changes in infarct size after 30 min ischemia followed by 90 min 233 
reperfusion, when the hearts are mounted on the isolated working heart apparatus TTC staining method was 234 
used.  *p < 0.05 in comparison with the control value. n=5 in each group.  235 
 236 
3. CONCLUSION 237 
In the present study, an attempt was made to synthesize a new NO-releasing ASA derivative 238 
and ascertain whether the release of NO from the MOL conjugate could be associated with 239 
enhanced myocardial circulation, and consequently, giving a chance to the survival of cardiac 240 
cells and tissues by preserving the oxygen supply via the dilation of coronary vessels. 241 
Based on our observations, the new molecule ERJ-500 appears to be nontoxic and stable 242 
under oxidative conditions. Furthermore, our pharmacological studies indicate vasoactive and 243 
anti-ischemic properties for the molecule. However, further in vivo studies are needed to 244 
investigate the effect on whole organism.  245 
 246 
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4. EXPERIMENTAL  247 
4.1. Chemistry 248 
MOL derivative 7 was prepared according to literature procedures [37]. All reagents were 249 
purchased from commercial suppliers and used without further purification. TLC was 250 
performed on Kieselgel 60 F254 (Merck, Darmstadt, Germany) with detection by UV-light 251 
(254 nm) and immersing into sulfuric acidic ammonium-molibdenate solution followed by 252 
heating. Flash column chromatography was performed on Silica gel 60 (Merck 0.040-0.063 253 
mm). Organic solutions were dried over Na2SO4 or MgSO4 and concentrated in vacuum. The 254 
1
H NMR (400 MHz) and 
13
C NMR (101 MHz) spectra were recorded with a Bruker DRX-400 255 
spectrometer at 25 ºC. Chemical shifts are referenced to Me4Si (0.00 ppm for 
1
H) and to the 256 
residual solvent signals (CDCl3: 77.1 for 
13
C). MALDI-TOF MS analyses of the compounds 257 
were carried out in the positive reflectron mode using a BIFLEX III mass spectrometer 258 
(Bruker, Karlsruhe, Germany) equipped with delayed-ion extraction. 2,5-Dihydroxybenzoic 259 
acid (DHB) was used as matrix and F3CCOONa as cationising agent in DMF.  260 
 261 
Compound 5 262 
Compound 4 (4.37 g, 10 mmol) was dissolved in dry dichloromethane (50 ml) and Et3N (2 263 
ml) was added to the stirred solution. Compound 3 (1.99 g, 10 mmol) dissolved in dry 264 
dichloromethane (10 ml) was added dropwise at 0 °C to the reaction mixture and it was stirred 265 
for 5 h at room temperature. The reaction mixture was quenched with satd. aq. NaHCO3 (30 266 
ml), stirred for further 15 min, then it was diluted with  dichloromethane (100 ml) and 267 
extracted with 10% NaHSO4  (30 ml ) and water (30 ml), dried over Na2SO4, filtered and 268 
evaporated at 35 
o
C in vacuum. The crude product was purified by flash column 269 
chromatography (n-hexane:acetone 7:3) to give 5 as a pale yellow syrup (4.0 g, 67%). Rf 0.34 270 
(n-hexane:acetone 7:3);
1
H NMR (400 MHz, CDCl3): δ 8.03 (dd, J = 7.8 Hz, J = 1.8 Hz, 1H, 271 
arom), 7.53 (td, J = 7.8 Hz, J = 1.8 Hz, 1H, arom), 7.47–7.45 (m, 6H, arom), 7.30–7.19 (m, 272 
10H, arom), 7.08 (dd, J = 8.1 Hz, J = 0.8 Hz, 1H), 4.41–4.39 (m, 2H, TEG-CH2), 3.78–3.76 273 
(m, 2H, TEG-CH2), 3.70–3.65 (m, 10H, 5 x TEG-CH2), 3.23 (t, J = 5.2 Hz, 2H, TEG-CH2), 274 
2.34 (s, 3H, CH3 Ac); 
13
C NMR (101 MHz, CDCl3): δ 169.9 (1C, Cq Ac), 164.5 (1C COO), 275 
150.8 (1C, Cq arom), 144.2 (3C, Cq arom), 134.0, 132.0, 128.8, 127.9, 127.0, 126.1, 123.9 276 
(19C, arom), 123.3 (1C, Cq arom), 86.6 (1C, Cq Tr), 70.9, 70.8, 70.7, 69.2, 64.4, 63.4 (8C, 8 x 277 
TEG-CH2), 21.10 (1C, CH3 Ac); MS (MALDI-TOF): m/z calcd for C36H38NaO8: 621.25 278 
[M+Na]
+
; found: 621.32.  279 
 280 
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Compound 6 281 
Compound 5 (1.2 g, 2.0 mmol) was added to the mixture of hexafluoroisopropanol (7.5 ml), 282 
BF3·Et2O (50 µl, 0.2 equiv.) and Et3SiH (1.2 ml, 3.8 equiv.). After complete conversion of the 283 
starting compound (cc. 15 min) the reaction was quenched with satd. aq. NaHCO3 solution (2 284 
ml). The mixture was concentrated in vacuum and the residue was purified by flash column 285 
chromatography (n-hexane:acetone 1:1) to give compound 6 as a colourless syrup (460 mg, 286 
65%). Rf 0.25 (n-hexane:acetone 1:1); 
1
H NMR (400 MHz, CDCl3): δ 8.05 (dd, J = 7.8 Hz, J 287 
= 1.6 Hz, 1H, arom), 7.56 (td, J = 7.9 Hz, J = 1.6 Hz, 1H, arom), 7.32 (td, J = 7.6 Hz, J = 1.2 288 
Hz, 1H, arom), 7.11 (dd, J = 8.1 Hz, J = 1.2 Hz, 1H, arom), 4.45–4.43 (m, 2H, TEG-CH2), 289 
3.81–3.78 (m, 2H, TEG-CH2), 3.74–3.65 (m, 10H, 5 x TEG-CH2), 3.60–3.58 (m, 2H, TEG-290 
CH2), 2.62 (s, 1H, TEG-OH), 2.36 (s, 3H, CH3 Ac); 
13
C NMR (101 MHz, CDCl3): δ 169.9 291 
(1C, Cq COO), 164.5 (1C, Cq Ac), 150.8 (1C, Cq arom), 134.1, 132.0, 126.1, 123.9 (4 C, 292 
arom), 123.2 (1C, Cq arom), 72.5, 70.8, 70.7, 70.6, 70.4, 69.2, 64.3, 61.8 (8C, 8 x TEG-CH2), 293 
21.1 (1C, CH3 Ac); MS (MALDI-TOF): m/z calcd for C17H24NaO8: 379.36 [M+Na]
+
; found: 294 
379.21.  295 
  296 
Compound ERJ-500 297 
The starting materials were dried over P2O5 overnight. Compound 7 (2.01 g, 6 mmol) was 298 
suspended in dry acetonitrile (100 ml) and compound 6 (2.49 g, 7 mmol) dissolved in dry 299 
acetonitrile (10 ml) was added. The reaction mixture was stirred at reflux temperature for 2 h, 300 
then it was evaporated. The crude product was purified by flash column chromatography (n-301 
hexane: acetone 6:4 →1:1) to give ERJ-500 as a colorless syrup (758 mg, 41%). 302 
Rf 0.16 (CH2Cl2:acetone 8:2)
; 1
H NMR (400 MHz, CDCl3): δ 8.03 (dd, J = 7.9 Hz, J = 1.7 Hz, 303 
1H, arom), 7.7 s1H, CH sydnone, 7.56 (ddd, J = 8.1, 7.4, 1.8 Hz, 1H, arom), 7.31 (td, J = 7.7 304 
Hz, 1.1 Hz, 1H, arom), 7.10 (dd, J = 8.1 Hz, J = 1.1 Hz, 1H, arom), 4.43– 4.41 (m, 2H, CH2 305 
morpholine), 4.26–4.24 (m, 2H, CH2 morpholine), 3.94–3.92 (m, 4H, 2 x TEG-CH2), 3.80 –306 
3.78 (m, 2H, CH2 morpholine), 3.74–3.72 (m, 2H, CH2 morpholine), 3.68-3.63 (m, 8H, 4 x 307 
TEG-CH2), 3.51–3.49 (m, 4H, 2 x TEG-CH2), 2.35 (s, 3H, CH3 Ac); 
13
C NMR (101 MHz, 308 
CDCl3): δ 174.2 (1C, Cq carbamate), 169.7 (1C, Cq COO), 164.4 (1C, Cq Ac), 161.2 (1C, Cq 309 
sydnone), 150.6 (1C, Cq arom), 133.8, 131.8, 125.9, 123.7 (4C, arom), 123.2 (1C, Cq arom), 310 
70.6, 70.5, 69.3, 69.0, 65.4, 64.6, 64.3, 54.6 (13C, 1 x sydnone-C, 4 x morpholine-CH2, 8 x 311 
TEG-CH2), 20.9 (1C, CH3 Ac). MS (MALDI-TOF): m/z calcd for C24H32N4NaO11: 575.20 312 
[M+Na]
+
; found: 575.31. 313 
 314 
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4.2. Oxidation by synthetic porphyrin and the chemical Fenton system 315 
Two reactions were carried out to test the stability of ERJ-500 molecule under oxidative 316 
conditions, based on the method as reported by Csepanyi et al. [42] recently, with minor 317 
modifications as follows: 50 µl of ERJ-500 dissolved in acetonitrile was used for synthetic 318 
porphyrin oxidation in 10 mM concentration. 400 µl of ERJ-500 in 2.5 mM concentration for 319 
the Fenton reaction. Samples were drawn at 1 h in the Fenton reactions prior to injecting them 320 
instantly to the HPLC and further investigation. Reaction mixtures for blank contained 321 
acetonitrile only without ERJ-500. The control mixtures contained no peroxide. 322 
 323 
4.3. Biological characterization 324 
 325 
Determination of cytotoxicity by MTT assay 326 
Assessment of the cytotoxicity of the ERJ-500, ASA, and MOL on cellular survival was 327 
accomplished using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 328 
assay based on the method described by Csepanyi et al. [42]. Briefly, H9c2 cells were treated 329 
with 100 nM, 1 µM, 10 µM, 100 µM of ERJ-500, 100 µM of MOL, 100 µM of ASA and 1% 330 
H2O2 (positive control) containing medium for 24 h on 96 well plates. Then, MTT solution 331 
was added to the medium and incubated for 3.5 h at 37 °C. After eliminating the solution 332 
from the cells, isopropanol was added and incubated for 0.5 h at 37 °C to dissolve the 333 
formazan aggregates. Absorbance was measured at 570 nm and 690 nm.  334 
 335 
Animals  336 
Female Sprague Dawley (SD) rats with an average weight of 248 ± 6 g were used in the 337 
present study. Animals were nutrified with standard rodent chow pellets (R/M-Z+H, ssniff 338 
Spezialdiäten GmbH, Soest, Germany) ad libitum with free access to water and kept at an 339 
ambient temperature of 25 ± 2 °C, with a relative humidity of 55 ± 5%, and a 12-hour light-340 
dark cycle. All animals were treated according to the “Principles of Laboratory Animal Care” 341 
formulated by the National Society for Medical Research, and the “Guide for the Care and 342 
Use of Laboratory Animals” prepared by the National Academy of Sciences and published by 343 
the National Institutes of Health (NIH Publication no. 86-23, revised in 1996). Breeding and 344 
handling of animals were approved by the Institutional Animal Care and Use Committee of 345 
the University of Debrecen, Debrecen, Hungary. 346 
 347 
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Determination of hemolytic activity 348 
Hemolysis tests were performed as described by Roka et al. [43] with some minor 349 
modifications. Rat blood samples were collected to K3EDTA containing vacuum tubes (BD, 350 
Plymouth, UK) and were treated with 100 nM, 1 µM, 10 µM, 100 µM ERJ-500, 100 µM of 351 
MOL and the same concentration of ASA in phosphate buffered saline (PBS). The percentage 352 
of hemolysis was expressed as the ratio of hemoglobin in the supernatant of the different 353 
chemical solutions related to the hemoglobin concentration after the complete hemolysis of 354 
erythrocytes in water. 355 
 356 
Langendorff heart preparation and assessment of heart rate and coronary flow 357 
Rats were anesthetized with an intraperitoneal pentobarbital sodium injection (60 mg/kg), 358 
with heparin as an anticoagulant (1000 U/kg). Following the induction of deep anesthesia, 359 
chest cavities were opened, hearts were excised and placed in ice-cold modified Krebs-360 
Henseleit bicarbonate (KHB) buffer (containing 118 mM NaCl, 5.8 mM KCl, 1.8 mM CaCl2, 361 
25 mM NaHCO3, 0.36 mM KH2PO4, 1.2 mM MgSO4, and 5.0 mM glucose). After excision, 362 
aortas were cannulated and each heart was perfused with modified KHB buffer at a filling 363 
pressure of 100 cm of water, using the “non-working” Langendorff mode for 5 min in order to 364 
flush blood out from the myocardium. The setup was assembled with two buffer-chambers at 365 
the same constant pressure. The one contained the KHB buffer only, the other contained ERJ-366 
500 dissolved into the KHB buffer at different concentrations (1 µM, 10 µM, 30 µM, 100 367 
µM). At the end of the washout period, baseline cardiac parameters were registered, including 368 
coronary flow (CF) and heart rate (HR), and the inflow was switched to serve the hearts from 369 
the chamber containing ERJ-500 for 10 min. Next, 10 min of washout period, followed by 10 370 
min of adding once more the ERJ-500 containing buffer. A continuous pressure signal was 371 
recorded during the whole experiment with the help of a pressure transducer (ADInstruments, 372 
PowerLab, Castle Hill, Australia), which was calibrated before each experiment. HR was 373 
calculated from the continuously recorded pressure signal. CF was assessed by the time-374 
collecting of the coronary effluent. 375 
Isolated working heart preparation to assess cardiac parameters and infarct size 376 
To measure cardiac function, isolated working heart preparations were carried out based on a 377 
previously described method by Czompa et al [44] on Sprague Dawley female rats (n=6) 378 
divided into two groups. After completing the isolated working heart preparation procedure 379 
followed by 10 minutes washout period, we registered the baseline working heart parameters 380 
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such as aortic flow [45], coronary flow (CF), aortic pressure (AOP), heart rate (HR) and 381 
derivated aortic pressure (AOdP/dT). Cardiac output (CO) was calculated by the sum of AF 382 
and CF and we got stroke volume (SV) by dividing the CO with HR. In the treated group, 383 
ERJ-500 was added to the KHB buffer by a dilution of a previously prepared stock solution, 384 
creating a 100 µM concentration of ERJ-500 in the heart inflow. The molecule-containing 385 
KHB buffer was presented after the washout and baseline registration period for 5 mins, 386 
followed by a 30 min ischemia followed by 90 min reperfusion. Results of AOP, AOdP/dT, 387 
CO and AF are included in the supplementary material. 388 
To determine the degree of the infarcted area in the myocardium, triphenyl tetrazolium 389 
chloride (TTC) staining was performed according to a previously presented study by Czompa 390 
et al [46]. Briefly, following ischemia and reperfusion, 50 ml of 1 % TTC solution was 391 
perfused through the myocardium. Then, hearts were frozen, sectioned, digitalized and all 392 
heart sections were blotted dry and weighed. Risked and infarcted areas were quantified by an 393 
open-source planimetry software Fiji [47]. Percentage of the infarcted area compared to the 394 
whole risked area of the myocardium is represented on a bar chart.  395 
 396 
Statistical analyses 397 
All data are presented as the average magnitudes of each outcome in a group ± standard error 398 
of the mean [42]. Statistical analysis was performed using t-test or one- or two-way analysis 399 
of variance (ANOVA), followed by Tukey’s multiple comparisons test with GraphPad Prism 400 
software for Windows (GraphPad Software Inc., La Jolla, CA, USA). Probability values (p) 401 
less than 0.05 were considered statistically significant.  402 
 403 
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